Cloeckaert Axel, Jacques Isabelle, Grilló Maria Jesus, Marín Clara M, Grayon Maggy, Blasco Jose-Maria, Verger Jean-Michel
Laboratoire de Pathologie Infectieuse et Immunologie, Unité BioAgresseurs Santé et Environnement, Institut National de la Recherche Agronomique, Nouzilly 37380, France.
Vaccine. 2004 Jul 29;22(21-22):2827-35. doi: 10.1016/j.vaccine.2004.01.001.
The live attenuated Brucella melitensis Rev.1 strain is considered the best vaccine available for the prophylaxis of brucellosis in sheep caused by either B. melitensis or Brucella ovis. However, its application stimulates antibody responses in vaccinated animals indistinguishable by the current conventional serological tests from those observed in infected animals. The periplasmic protein BP26 and the outer membrane protein (OMP) Omp31 are immunodominant antigens in the serological responses of B. melitensis and B. ovis infected sheep, respectively. Accordingly, vaccine strain Rev.1 single and double deletion mutants of the bp26 and omp31 genes were developed, based on the principle that the use of such mutants as vaccines in association with diagnostic tests based on BP26 and Omp31 antigens would allow the serological differentiation between infected and vaccinated animals. The deletion mutants obtained were indistinguishable from the parental Rev.1 strain by conventional bacteriological and typing tests. The expression of their major surface antigens, as determined by reactivity with specific monoclonal antibodies (MAbs), remained unaffected, i.e. smooth-lipopolysaccharide (S-LPS) and OMPs besides in the expression of the antigens whose respective genes were deleted. The bp26 and omp31 deletions did not modify the kinetics of splenic infection nor the residual virulence of Rev.1 in the BALB/c mouse model. Vaccination of BALB/c mice with the deletion mutants conferred significant protective immunity against B. melitensis strain H38 or B. ovis strain PA challenges, to the same extent as that induced by parental Rev.1 strain. Thus, these Rev.1 bp26 or omp31 deletion mutants are promising vaccine candidates against B. melitensis and B. ovis infections and will be further evaluated in sheep.
减毒活布鲁氏菌Rev.1菌株被认为是预防由羊种布鲁氏菌或绵羊布鲁氏菌引起的绵羊布鲁氏菌病的最佳可用疫苗。然而,其应用会刺激接种动物产生抗体反应,目前的常规血清学检测无法区分这些反应与感染动物的反应。周质蛋白BP26和外膜蛋白(OMP)Omp31分别是羊种布鲁氏菌和绵羊布鲁氏菌感染绵羊血清学反应中的免疫显性抗原。因此,基于将此类突变体用作疫苗并结合基于BP26和Omp31抗原的诊断测试可实现感染动物和接种动物血清学区分的原则,开发了bp26和omp31基因的疫苗株Rev.1单缺失和双缺失突变体。通过常规细菌学和分型试验,获得的缺失突变体与亲本Rev.1菌株无法区分。通过与特异性单克隆抗体(MAb)反应性测定,其主要表面抗原的表达未受影响,即除了各自基因被缺失的抗原表达外,光滑脂多糖(S-LPS)和OMPs的表达未受影响。bp26和omp31缺失并未改变脾脏感染的动力学,也未改变Rev.1在BALB/c小鼠模型中的残余毒力。用缺失突变体对BALB/c小鼠进行疫苗接种可对羊种布鲁氏菌H38菌株或绵羊布鲁氏菌PA菌株的攻击提供显著的保护性免疫,其程度与亲本Rev.1菌株诱导的免疫程度相同。因此,这些Rev.1 bp26或omp31缺失突变体是抗羊种布鲁氏菌和绵羊布鲁氏菌感染的有前景的候选疫苗,并将在绵羊中进行进一步评估。